These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7868749)

  • 1. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi.
    Saenz-Santamaría MC; Reed JA; McNutt NS; Shea CR
    J Cutan Pathol; 1994 Oct; 21(5):393-7. PubMed ID: 7868749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 expression is rare in cutaneous melanomas.
    Saenz-Santamaría MC; McNutt NS; Bogdany JK; Shea CR
    Am J Dermatopathol; 1995 Aug; 17(4):344-9. PubMed ID: 8600797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intercellular adhesion molecule 1 (ICAM-1) and bcl-2 are differentially expressed in early evolving malignant melanoma.
    Collins KA; White WL
    Am J Dermatopathol; 1995 Oct; 17(5):429-38. PubMed ID: 8599446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. bcl-2 protein expression in melanocytic neoplasms of the skin.
    Ramsay JA; From L; Kahn HJ
    Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
    Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
    Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 expression in human melanocytes and melanocytic tumors.
    van den Oord JJ; Vandeghinste N; De Ley M; De Wolf-Peeters C
    Am J Pathol; 1994 Aug; 145(2):294-300. PubMed ID: 8053490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
    Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
    Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma.
    Leiter U; Schmid RM; Kaskel P; Peter RU; Krähn G
    Arch Dermatol Res; 2000 May; 292(5):225-32. PubMed ID: 10867810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma.
    Lohmann CM; Iversen K; Jungbluth AA; Berwick M; Busam KJ
    Am J Surg Pathol; 2002 Oct; 26(10):1351-7. PubMed ID: 12360050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi.
    Cerroni L; Soyer HP; Kerl H
    Am J Dermatopathol; 1995 Feb; 17(1):7-11. PubMed ID: 7695015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased tenascin expression in melanocytic tumors.
    Tuominen H; Kallioinen M
    J Cutan Pathol; 1994 Oct; 21(5):424-9. PubMed ID: 7532653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth dynamics of acquired melanocytic nevi. Higher reactivity of proliferating cell nuclear antigen in junctional and compound nevi than intradermal nevi.
    Tokuda Y; Saida T; Mukai K; Takasaki Y
    J Am Acad Dermatol; 1994 Aug; 31(2 Pt 1):220-4. PubMed ID: 7913717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant melanoma with paradoxical maturation.
    Ruhoy SM; Prieto VG; Eliason SL; Grichnik JM; Burchette JL; Shea CR
    Am J Surg Pathol; 2000 Dec; 24(12):1600-14. PubMed ID: 11117780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expression of retinoblastoma protein in cutaneous melanomas.
    Saenz-Santamaría MC; McNutt NS; Shea CR
    Br J Dermatol; 1995 Dec; 133(6):890-5. PubMed ID: 8547040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
    Nazarian RM; Prieto VG; Elder DE; Duncan LM
    J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
    Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
    Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma-associated expression of transforming growth factor-beta isoforms.
    Van Belle P; Rodeck U; Nuamah I; Halpern AC; Elder DE
    Am J Pathol; 1996 Jun; 148(6):1887-94. PubMed ID: 8669474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
    Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
    Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma.
    Böni R; Doguoglu A; Burg G; Müller B; Dummer R
    J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):416-8. PubMed ID: 8784279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.